Please use this identifier to cite or link to this item:
Título : An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
Autor : Harari, Alexandre, Bart, Pierre-Alexandre, Stöhr, Wolfgang, Tapia, Gonzalo, García Cabezas, Miguel Ángel, Medjitna-Rais, Emmanuelle, Burnet, Séverine, Cellerai, Cristina, Erlwein, Otto, Barber, Tristan, Moog, Christiane, Liljeström, Peter, Wagner, Ralf, Wolf, Hans, Kraehenbuhl, Jean-Pierre, Esteban, Mariano, Heeney, Jonathan L., Frachette, Marie-Joelle, Tartaglia, James, McCormack, Sheena, Babiker, Abdel, Weber, Jonathan, Pantaleo, Giuseppe
Palabras clave : EuroVacc 02 clinical trial
New York vaccinia virus (NYVAC)
Human immunodeficiency virus (HIV)-1
T-cell immune response
DNA C plus NYVAC C vaccine
HIV vaccines
Fecha de publicación : 14-Jan-2008
Editor: Rockefeller University Press
Resumen: The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C isolate, CN54. 40 volunteers were randomized to receive DNA C or nothing on day 0 and at week 4, followed by NYVAC C at weeks 20 and 24. The primary immunogenicity endpoints were measured at weeks 26 and 28 by the quantification of T cell responses using the interferon enzyme-linked immunospot assay. Our results indicate that the DNA C plus NYVAC C vaccine regimen was highly immunogenic, as indicated by the detection of T cell responses in 90% of vaccinees and was superior to responses induced by NYVAC C alone (33% of responders). The vaccine-induced T cell responses were (a) vigorous in the case of the env response (mean 480 spot-forming units/106 mononuclear cells at weeks 26/28), (b) polyfunctional for both CD4 and CD8 T cell responses, (c) broad (the average number of epitopes was 4.2 per responder), and (d) durable (T cell responses were present in 70% of vaccinees at week 72). The vaccine-induced T cell responses were strongest and most frequently directed against Env (91% of vaccines), but smaller responses against Gag-Pol-Nef were also observed in 48% of vaccinees. These results support the development of the poxvirus platform in the HIV vaccine field and the further clinical development of the DNA C plus NYVAC C vaccine regimen.
Descripción : 15 pages, 8 figures.-- PMID: 18195071 [PubMed].-- PMCID: PMC2234371.
Versión del editor:
ISSN: 0022-1007
DOI: 10.1084/jem.20071331
Citación : The Journal of Experimental Medicine 205(1): 63-77 (2008)
Appears in Collections:(CNB) Artículos

Files in This Item:
File Description SizeFormat 
Harari_JExpMed_2008.pdf6,64 MBAdobe PDFView/Open
Show full item record

Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.